Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Betaseron

Known as: Beta Seron, Beta-Seron 
 
National Institutes of Health

Related topics

Related topics

5 relations
Betaferoninterferon beta-1b 0.3 MG Injection [Betaseron]

Broader (3)

Interferon-betaRecombinant Interferon Betainterferon beta-1b

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Cellular self-assembly into 3D microtissues enhances the angiogenic activity and functional neovascularization capacity of human cardiopoietic stem cells
While cell therapy has been proposed as next-generation therapy to treat the diseased heart, current strategies display only… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 6
Is this relevant?
Highly Cited
2016
Highly Cited
2016
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
Objective: To assess outcomes for patients treated with interferon beta-1b immediately after clinically isolated syndrome (CIS… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2013
2013
Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice
PurposeInterferon beta is commonly used as therapeutic in the first line of therapy for multiple sclerosis. However, depending on… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table I
Is this relevant?
Review
2010
Review
2010
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis.
Multiple sclerosis is a chronic autoimmune disease of the central nervous system for which a number of disease-modifying… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis
An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFNβ-1a-Avonex) was conducted to… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Review
2004
Review
2004
Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis
Protein- and peptide-based disease-modifying agents for multiple sclerosis (MS), including interferon beta (IFNβ) and glatiramer… Expand
  • table 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX.
The aim of this 1 week study was to compare the biologic effects induced by Betaseron and AVONEX using their approved dose, route… Expand
Is this relevant?
1997
1997
Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: Plight of the practicing neurologist
The recently reported decrease in beta interferon (IFNβ) efficacy induced by anti-IFNβ antibodies1 has prompted Berlex… Expand
Is this relevant?
1996
1996
Detection of altered T helper 1 and T helper 2 cytokine production by peripheral blood mononuclear cells in patients with multiple sclerosis utilizing intracellular cytokine detection by flow…
Production of T helper 1 and T helper 2 cytokines was investigated in peripheral blood mononuclear cells (PBMCs) from multiple… Expand
Is this relevant?
1995
1995
The use of Zwittergent 3-14 in the purification of recombinant human interferon-beta Ser17 (Betaseron).
A new method for purifying human interferon-beta SER17 from E. coli-derived inclusion bodies has been developed. This procedure… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE